Showing results (221-230 of 246) with videos related to

Sort By:
Pageof 25
Acta Anaesthesiologica Scandinavica|October 6, 1997
Retardation of pain development: a case of recovery from congenital insensitivity to painT H Zhou, X H Ren, D L Yin, et al.
Cytogenetic and Genome Research|March 17, 2009
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosusY L Wu, Y Yang, E K Chung, et al.
Scientific Reports|June 9, 2015
Coherent Generation of Photo-Thermo-Acoustic Wave from Graphene SheetsYichao Tian, He Tian, Y L Wu, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 1, 2007
Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patientsG-C Zhang, J-Y Lin, Z Wang, et al.
Tissue Antigens|June 27, 2012
The HLA-DRB1 gene and Graves disease in Taiwanese children: a case-control and family-based studyY-L Wu, T-Y Chang, C-C Chu, et al.
Cell Death & Disease|June 24, 2016
Junctophilin 3 expresses in pancreatic beta cells and is required for glucose-stimulated insulin secretionL Li, Z-F Pan, X Huang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 28, 2012
Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label studyY Sun, Y-L Wu, C-C Zhou, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|December 14, 2011
Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinomaM-T Wang, G Chen, S-J An, et al.
Tissue Antigens|October 2, 2012
The HLA-B gene and Hashimoto disease in Han Chinese children: a case-control and family-based studyC-Y Huang, T-Y Chang, C-C Chu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN studyA T Shaw, B J Solomon, E Felip, et al.
Pageof 25